

# Diane K Reyes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1125111/publications.pdf>

Version: 2024-02-01

26  
papers

1,531  
citations

516710

16  
h-index

610901

24  
g-index

27  
all docs

27  
docs citations

27  
times ranked

2131  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3960-3967.	1.6	279
2	The biology and treatment of oligometastatic cancer. <i>Oncotarget</i> , 2015, 6, 8491-8524.	1.8	243
3	The Role of Functional MR Imaging in the Assessment of Tumor Response after Chemoembolization in Patients with Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 505-512.	0.5	195
4	Unresectable Hepatocellular Carcinoma: Serial Early Vascular and Cellular Changes after Transarterial Chemoembolization as Detected with MR Imaging. <i>Radiology</i> , 2009, 250, 466-473.	7.3	178
5	Single-Center Phase II Trial of Transarterial Chemoembolization With Drug-Eluting Beads for Patients With Unresectable Hepatocellular Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2009, 15, 526-532.	2.0	121
6	Phase II Study of Chemoembolization With Drug-Eluting Beads in Patients With Hepatic Neuroendocrine Metastases: High Incidence of Biliary Injury. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 449-459.	2.0	91
7	Intrahepatic Cholangiocarcinoma Treated with Local-Regional Therapy: Quantitative Volumetric Apparent Diffusion Coefficient Maps for Assessment of Tumor Response. <i>Radiology</i> , 2012, 264, 285-294.	7.3	60
8	Neuroendocrine Liver Metastasis Treated by Using Intraarterial Therapy: Volumetric Functional Imaging Biomarkers of Early Tumor Response and Survival. <i>Radiology</i> , 2013, 266, 502-513.	7.3	54
9	Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part II. Response Stratification Using Volumetric Functional Criteria after Intraarterial Therapy. <i>Radiology</i> , 2013, 268, 431-439.	7.3	49
10	Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part I. Identification and Validation of Volumetric Functional Response Criteria. <i>Radiology</i> , 2013, 268, 420-430.	7.3	41
11	Islet Cell Liver Metastases: Assessment of Volumetric Early Response with Functional MR Imaging after Transarterial Chemoembolization. <i>Radiology</i> , 2012, 264, 97-109.	7.3	40
12	Comparison of quantitative $^{90}\text{Y}$ SPECT and non- $^{18}\text{F}$ PET imaging in post-therapy radioembolization of liver cancer. <i>Medical Physics</i> , 2016, 43, 5779-5790.	3.0	32
13	Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. <i>Radiology</i> , 2015, 277, 594-603.	7.3	31
14	Prospective Comparison of PET Imaging with PSMA-Targeted $^{18}\text{F}$ -DCFPyL Versus $^{18}\text{F}$ for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 183-188.	5.0	27
15	Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. <i>European Radiology</i> , 2015, 25, 380-390.	4.5	24
16	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. <i>World Journal of Urology</i> , 2019, 37, 2623-2629.	2.2	21
17	Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. <i>Medical Oncology</i> , 2020, 37, 60.	2.5	12
18	CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer. <i>Prostate</i> , 2021, 81, 127-134.	2.3	9

#	ARTICLE	IF	CITATIONS
19	The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer. <i>BJU International</i> , 2020, 126, 191-201.	2.5	7
20	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. <i>Medical Oncology</i> , 2022, 39, 63.	2.5	6
21	PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. <i>Urology Case Reports</i> , 2019, 23, 72-74.	0.3	5
22	Oligometastatic Prostate Cancer to the Navicular Bone: Case Report. <i>Urology Case Reports</i> , 2015, 3, 59-62.	0.3	2
23	Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer. <i>Medical Oncology</i> , 2021, 38, 80.	2.5	2
24	Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5020-5020.	1.6	2
25	A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy. <i>Urology Case Reports</i> , 2016, 6, 45-46.	0.3	0
26	Prospective phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: Efficacy analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4124-4124.	1.6	0